News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
156
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8287
|
|
Created
|
12/30/04
|
Type
|
Free
|
| Moderators | |||
Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer
Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation
The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia
Short-term Toxicity Study of DHA-dFdC
AIkido Pharma Inc. seeks to enhance shareholder value not only through exceptional business performance and practices,
but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual
and institutional investor includes stock price and history, upcoming events and presentations and financial documents.
AIkido Pharma Inc. is traded on the Nasdaq under the ticker symbol AIKI.
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
The Spherix platform contains patented technology from leading universities and researchers and we seek to develop
our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.
https://ir.aikidopharma.com/stock-information/
$AIKI Spherix Incorporated, a biotechnology company,focuses on developing small-molecule anti-cancer therapeutics.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company's platform consists of patented technology from leading universities and researchers and in the process of developing an
innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at
Austin and Wake Forest University.
It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing pancreatic cancer.
Spherix Incorporated was founded in 1967 and is based in New York, New York.
AI
